Nephrosant
NephroSant is a privately-held renal diagnostics company founded in 2017 in Brisbane, California, developing biomarker-based tools for early detection and lifetime monitoring of kidney health and injury, primarily serving clinical nephrology and dialysis customers.
- Company typePrivate
- Founded2017
- HeadquartersBrisbane, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Nephrosant firmographics
Firmographics- Name
- Nephrosant
- Website
- https://nephrosant.com
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 51–100 employees
- Short description
- NephroSant is a privately-held renal diagnostics company founded in 2017 in Brisbane, California, developing biomarker-based tools for early detection and lifetime monitoring of kidney health and injury, primarily serving clinical nephrology and dialysis customers.
- Ownership category
- akta.pro rank
Nephrosant industry classification
Industry- Product category
- Kidney Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)
Keywords
Where Nephrosant is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- United States
- HQ region
- North America
Markets served
Nephrosant business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Nephrosant product offering
Product offeringCore offering
Nephrosant develops and delivers diagnostic tools for the early detection and lifetime monitoring of kidney health and injury. The company focuses on biomarker-based testing approaches aimed at identifying kidney damage earlier than conventional methods, enabling clinicians to track renal function over time.
Differentiator
Problem solved
Functional benefit
Products and services
- Kidney Health Diagnostic Tool A diagnostic tool for early detection and lifetime monitoring of kidney health and injury, intended for clinical use by healthcare providers and nephrology specialists.
Companies that use Nephrosant
Customer profileIdeal customer profiles2 records
Nephrosant technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nephrosant competitors and assessment
Company assessmentBroad incumbents
- Bio-Techne: Bio-Techne supplies kidney-injury biomarker reagents (e.g., NGAL, KIM-1) and diagnostic tools to research and clinical labs, making it a broad incumbent in the renal biomarker/diagnostic supply chain that NephroSant competes against or partners with.
- ChemoCentryx (Amgen): Amgen's acquisition of ChemoCentryx brought Tavneos, approved for ANCA-associated vasculitis (a kidney-relevant disease), illustrating the strategic value of nephrology assets; Amgen also operates in CKD therapeutics and is a comparable broad incumbent in kidney care.
- Quest Diagnostics: Quest Diagnostics is a major clinical reference lab offering kidney function testing (eGFR, microalbumin, cystatin C) and is a primary incumbent whose standard kidney panels NephroSant's novel biomarkers would need to displace or complement.
- DaVita: DaVita is the largest US dialysis provider and a strategic investor in NephroSant; it represents both the primary commercial channel opportunity and a broad incumbent in kidney care that could internalize or substitute competing diagnostics.
- Fresenius Medical Care: Fresenius is the world's largest dialysis services and products provider with growing interest in CKD diagnostics and home monitoring, providing a comparable incumbent channel and competitive threat to NephroSant's kidney monitoring business.
Others
- Eurofins Scientific: Eurofins operates a global network of clinical diagnostic laboratories, including specialty biomarker testing, and could serve as a contract lab partner or competitor for NephroSant's kidney diagnostic tests.
Emerging players
- ProKidney: ProKidney is a clinical-stage cell-therapy company focused on CKD/diabetic kidney disease, representing an adjacent emerging player in the kidney disease therapeutic/diagnostic space that targets the same patient population.
Direct peers
- EKF Diagnostics: EKF Diagnostics develops point-of-care clinical chemistry analyzers (including kidney-related markers like creatinine and eGFR) and aims at rapid kidney health diagnostics, comparable in customer channel (clinics/labs) and renal testing focus.
- Natera: Natera offers Renasight, a hereditary kidney disease genetic test, and broader organ-health biomarker diagnostics, overlapping with NephroSant's kidney diagnostic testing focus and clinical-channel distribution model.
- Renalytix (Verici Dx): Renalytix AI built a biomarker-based diagnostic (KidneyIntelX) for early-stage diabetic kidney disease risk assessment, directly comparable to NephroSant's early-detection kidney diagnostic mission in target customer and clinical use case.
Market position
Customer concentration
Nephrosant social profiles
Digital presenceNephrosant financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nephrosant leadership team
Management profileNumber of profiles
Profiles5 records
Nephrosant funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nephrosant M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nephrosant
What does Nephrosant do?
Nephrosant develops and delivers diagnostic tools for the early detection and lifetime monitoring of kidney health and injury. The company focuses on biomarker-based testing approaches aimed at identifying kidney damage earlier than conventional methods, enabling clinicians to track renal function over time.
When was Nephrosant founded?
Nephrosant was founded in 2017. It employs 51 to 100 people.
Where is Nephrosant based?
Nephrosant is headquartered in Brisbane, United States, in the North America region.
Who are Nephrosant's main competitors?
Broad incumbents on record are Bio-Techne, ChemoCentryx (Amgen), Quest Diagnostics, DaVita and Fresenius Medical Care. Eurofins Scientific is listed as an others. ProKidney is listed as an emerging player. Direct peers are EKF Diagnostics, Natera and Renalytix (Verici Dx).
Does Nephrosant have an API?
No public API is recorded for Nephrosant.
What industry is Nephrosant in?
Nephrosant's product category is Kidney Diagnostics. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status). Its NAICS code is 325413 and its SIC code is 2835.